These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 1069548

  • 1. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.
    Pinsky CM, Hirshaut Y, Wanebo HJ, Fortner JG, Miké V, Schottenfeld D, Oettgen HF.
    Ann N Y Acad Sci; 1976; 277(00):187-94. PubMed ID: 1069548
    [No Abstract] [Full Text] [Related]

  • 2. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB.
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy of human malignant melanoma with irradiated tumor cells, oral Bacillus Calmette-Guérin, and levamisole.
    Shibata HR, Jerry LM, Lewis MG, Mansell PW, Capek A, Marquis G.
    Ann N Y Acad Sci; 1976 Jun; 277(00):355-66. PubMed ID: 1069555
    [No Abstract] [Full Text] [Related]

  • 4. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB, Falk RE, Landi S, Ambus U, Samuel ES, Langer B.
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [Abstract] [Full Text] [Related]

  • 5. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB, Dent PB, Blajchman M, Muirhead WM, Price RA.
    Can Med Assoc J; 1977 Jul 09; 117(1):33-6. PubMed ID: 861909
    [Abstract] [Full Text] [Related]

  • 6. Bacillus Calmette-Guerin injections for melanoma immunotherapy: potential for a false-positive PET/CT.
    Sogge SM, Fotos JS, Tulchinsky M.
    Clin Nucl Med; 2015 Apr 09; 40(4):368-9. PubMed ID: 25674877
    [Abstract] [Full Text] [Related]

  • 7. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
    Tan JK, Ho VC.
    J Dermatol Surg Oncol; 1993 Nov 09; 19(11):985-90. PubMed ID: 8245304
    [Abstract] [Full Text] [Related]

  • 8. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
    Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rümke P.
    Eur J Cancer; 1993 Nov 09; 29A(9):1237-42. PubMed ID: 8343260
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM, Wells HB, Case LD, Spurr CL, White DR, Richards F, Muss HB, Jackson DV, Stuart JJ, Cooper MR.
    Cancer; 1985 Feb 15; 55(4):707-12. PubMed ID: 3967167
    [Abstract] [Full Text] [Related]

  • 10. Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report.
    Bilgi C, Brown NE, McPherson TA, Lentle B.
    Chest; 1979 Jun 15; 75(6):685-7. PubMed ID: 436519
    [Abstract] [Full Text] [Related]

  • 11. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM, Hutchins GM.
    Am J Dermatopathol; 1986 Aug 15; 8(4):331-5. PubMed ID: 3532854
    [Abstract] [Full Text] [Related]

  • 12. Calmette-Guerin bacillus treatment of experimental conjunctival malignant melanoma.
    Rutgard J, Peyman GA, Frenkel M, Saks S.
    Arch Ophthalmol; 1977 Dec 15; 95(12):2214-7. PubMed ID: 588117
    [Abstract] [Full Text] [Related]

  • 13. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White DS.
    Cancer; 1983 Jan 01; 51(1):57-60. PubMed ID: 6821809
    [Abstract] [Full Text] [Related]

  • 14. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
    Mavligit GM, Gutterman JU, Hersh EM.
    J Natl Cancer Inst; 1976 Oct 01; 57(4):749-51. PubMed ID: 1003526
    [Abstract] [Full Text] [Related]

  • 15. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin.
    Spitler LE, Levin AS, Wybran J.
    Cell Immunol; 1976 Jan 01; 21(1):1-19. PubMed ID: 764975
    [No Abstract] [Full Text] [Related]

  • 16. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH, Deutschmann EM, Schultheis W, Deicher H.
    Dev Biol Stand; 1976 Jan 01; 38():537-40. PubMed ID: 344106
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK, Ibrahim EM, Evers JA, Thomas JW, Murray RN, Spinelli JJ.
    Can Med Assoc J; 1983 Jun 01; 128(11):1291-5. PubMed ID: 6342739
    [Abstract] [Full Text] [Related]

  • 18. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP, Labandter HP, Hiles RW, Bodenham DC.
    Br J Plast Surg; 1978 Oct 01; 31(4):317-22. PubMed ID: 361132
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA, Das Gupta TK, Trippon M, Simo C, Sabet TY, Crispen R.
    Surg Gynecol Obstet; 1978 Feb 01; 146(2):230-2. PubMed ID: 622668
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.